Summary
GGT (Gamma-Glutamyl Transferase) is a liver enzyme that is exquisitely sensitive to alcohol consumption and bile duct dysfunction. It is the first liver marker to rise with even modest alcohol intake and returns to normal within weeks of abstinence — making it both a sensitive alcohol biomarker and a tool for monitoring treatment compliance. Elevated GGT alongside ALT or ALP helps pinpoint the type and site of liver disease.
GGT is found in the liver, bile ducts, kidney, pancreas, and intestine — but hepatic GGT is the dominant source in the serum. It plays a role in glutathione metabolism and amino acid transport across cell membranes.
GGT is more sensitive than ALT for alcohol-related liver disease: even 2–3 units of alcohol per day can raise GGT, and levels typically double or triple with heavy regular drinking. It normalises after 4–6 weeks of abstinence — a clinically useful timeframe for monitoring.
When GGT is elevated alongside ALP but ALT is relatively normal, a cholestatic (bile duct) problem — such as gallstones, primary biliary cholangitis, or intrahepatic cholestasis — is more likely. When GGT and ALT are both elevated, a hepatocellular (liver cell) problem is more likely.
What It Is
GGT (γ-glutamyl transpeptidase) is a membrane-bound glycoprotein enzyme found on the luminal surface of biliary epithelial cells and hepatocyte sinusoidal membranes. It catalyses the transfer of glutamyl groups from glutathione and other gamma-glutamyl peptides, playing a role in amino acid transport and glutathione recycling.
GGT is highly inducible by alcohol and certain drugs (particularly anti-epileptics, rifampicin, and warfarin) — hepatic microsomal enzyme induction causes GGT to rise even without direct liver damage. This means elevated GGT does not always indicate liver injury, but always warrants explanation.
Reference ranges vary significantly by sex: most UK labs quote < 50 U/L for women and < 70 U/L for men, though some labs use higher upper limits. GGT rises with age in both sexes.
Functions
Alcohol exposure marker
GGT is the most sensitive routine marker for alcohol-related liver disease — rising with even modest regular alcohol intake and normalising within 4–6 weeks of abstinence.
Biliary disease indicator
GGT and ALP both rise in bile duct obstruction and cholestatic liver disease, helping distinguish these from hepatocellular injury (where ALT predominates).
Metabolic risk marker
Population studies show GGT is an independent predictor of type 2 diabetes, cardiovascular disease, and all-cause mortality — likely reflecting oxidative stress and hepatic fat.
Drug and induction marker
Enzyme-inducing medications (anti-epileptics, rifampicin) raise GGT without liver damage. GGT elevation with normal ALT and ALP should prompt a medication review.
Reference Ranges
GGT — Gamma-Glutamyl Transferase
Measured in U/L| Status | Range (U/L) | What it means |
|---|---|---|
| Normal | < 50 (women) / < 70 (men) | No significant hepatic or biliary stress detected. |
| Mildly elevated | 50–150 | Mild elevation — consider alcohol intake, medication review, and NAFLD. |
| Elevated | > 150 | Significant elevation — alcohol excess, bile duct disease, or metabolic liver disease likely. |
Reference ranges differ by sex and laboratory. GGT naturally rises with age. Drug-induced elevation (anti-epileptics, rifampicin) can cause significant GGT rise without liver pathology. Always interpret in context.
Symptoms of Imbalance
GGT elevation is often asymptomatic. When symptoms are present, they reflect the underlying liver or bile duct condition.
- Low GGT is normal and not clinically significant.
- Often entirely asymptomatic
- Fatigue and malaise
- Right upper abdominal discomfort or tenderness
- Nausea and loss of appetite
- Jaundice (in significant biliary obstruction)
- Itching (in cholestatic disease)
- Dark urine and pale stools (bile duct obstruction)
Causes of Imbalance
- Low GGT is normal — hypothyroidism occasionally causes mildly low GGT.
- Alcohol consumption — the most common cause
- Non-alcoholic fatty liver disease (NAFLD)
- Bile duct obstruction (gallstones, cholangitis, primary biliary cholangitis)
- Enzyme-inducing medications (anti-epileptics, rifampicin, warfarin)
- Pancreatitis
- Hyperthyroidism
- Obesity and metabolic syndrome
FAQs
Yes — GGT is the most sensitive routine marker for alcohol excess. Drinking as little as 2–4 units daily can raise GGT, and heavy regular drinking typically causes levels 3–10× the upper limit of normal. Crucially, GGT returns to normal within 4–6 weeks of complete abstinence, making it a useful objective monitor of alcohol reduction.
Yes. Enzyme-inducing medications — including anti-epileptics (carbamazepine, phenytoin), rifampicin, and warfarin — raise GGT through hepatic microsomal induction without causing liver cell injury. GGT may also be mildly elevated in hyperthyroidism and obesity. A medication review is essential when GGT is elevated with normal ALT and ALP.
This pattern suggests a cholestatic (bile duct) problem rather than hepatocellular injury. GGT elevation confirms that an elevated ALP is from the liver (not bone) and points to bile duct pathology. Investigations would include liver ultrasound (for bile duct dilatation, gallstones) and testing for primary biliary cholangitis (anti-mitochondrial antibodies).
GGT is not a specific cancer marker, but it is elevated in liver, pancreatic, and bile duct cancers. In isolation, elevated GGT is not diagnostic of malignancy. However, very high GGT with other markers (elevated bilirubin, ALP, weight loss) warrants imaging. As part of routine screening, the most common causes remain alcohol and NAFLD.
The most effective interventions are: (1) reducing or stopping alcohol — GGT normalises within 4–6 weeks of abstinence; (2) losing weight — GGT falls significantly with a 5–10% reduction in body weight in NAFLD; (3) reviewing medications with a GP — if drugs are the cause, alternatives may be available. Coffee consumption (2–4 cups daily) is associated with lower GGT and may be hepatoprotective.
References
- Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38(4):263–355. View source
- Lim JS, et al. Is serum gamma-glutamyltransferase a risk factor for type 2 diabetes mellitus? Diabetes Res Clin Pract. 2010;88(2):e6–e9. View source
- Niemela O, Alatalo P. Biomarkers of alcohol consumption and related liver disease. Scand J Clin Lab Invest. 2010;70(5):305–312. View source